If fibromyalgia is autoimmune, removing the antibodies should have helped more than this

For five years the most hopeful idea in fibromyalgia research has been that the condition might turn out to be autoimmune. This week that idea got its first proper test in people, and the result is one you have to read slowly.

The idea came out of a 2021 paper from Andreas Goebel's group at the University of Liverpool, working with Karolinska and King's College London. They took IgG, the most common class of antibody in blood, from people with fibromyalgia and gave it to mice. The mice became more sensitive to pressure and to cold, moved around less, and gripped more weakly. Serum with the IgG stripped out of it did nothing. Antibodies from healthy donors did nothing (Journal of Clinical Investigation, 2021). That finding has held up since, most recently in the Journal of Physiology this April, where the transferred antibodies were shown to sensitise the mechanical sensors sitting in the skin itself (The Journal of Physiology, 2026).

Which gave the field a clean, testable prediction. If circulating antibodies are producing the pain, take the antibodies out and the pain should come down with them.

That is the trial that just reported. Sixty three adults with severe fibromyalgia, recruited across seven sites in north west England, were randomly assigned to weekly infusions under the skin of either rozanolixizumab, a drug already in use for myasthenia gravis that blocks the receptor responsible for keeping IgG in circulation and so clears antibodies out of the blood, or placebo, for up to 24 weeks, with a two week placebo period at the start that nobody was told about. The measure that counted was how much pain interfered with ordinary daily life, scored from zero to ten (The Lancet Rheumatology, 2026).

The drug group finished about half a point ahead of placebo.

Half a point. The authors' own verdict is that the drug "did not demonstrate broad efficacy in this severe fibromyalgia population," and that the improvement they did see was "not meaningful at a group level."

What the coverage will miss

The trial carried two thresholds for success, both written into the plan before anyone enrolled: a deliberately lenient one, fitting for an early study, and the conventional one almost every published trial is judged against. It cleared the lenient threshold. It missed the conventional one. Anything reporting that the study "met its primary endpoint" is citing the first number without the second. Both sit next to each other in the paper.

The second thing to be clear about is what was actually tested. Not the antibody theory. What was tested is whether lowering antibodies in everyone with severe fibromyalgia helps everyone with severe fibromyalgia, and the researchers say plainly that they had no way to identify which participants were carrying the relevant autoantibodies in the first place. A real effect in a subgroup could be sitting inside this result, averaged into invisibility by the people it was never going to touch. The theory could also just be wrong. This trial cannot separate those two possibilities, and it doesn't claim to.

Then there is who took part. Sixty three people, median age 47, most of them women, nearly all white, in one region of one country. A narrow slice, and it runs younger than most of the people who write to me about living with fibromyalgia.

On safety, nothing alarming: no serious adverse events on the drug during treatment, and headache, the most common complaint, came up as often on placebo.

In fairness: the trial was funded by UCB, which makes the drug, and Goebel is named on a patent application covering this class of drug in fibromyalgia. Both are declared in the paper. The result was published as a miss anyway, which is not nothing.

Where this leaves an ordinary morning

So nobody yet knows whether fibromyalgia is antibody driven, an uncomfortable thing to be told when you're the one living in the body under discussion. Especially when the question sitting underneath it, is fibromyalgia a real disease, is one most people with it have already been made to answer too many times.

What I keep running into in my classes is a particular kind of tiredness in people who have followed this research for a decade. A mechanism arrives, gets a hopeful write up, then the trial lands smaller than the story. After enough rounds of that people stop reading the research, and some quietly stop trying things as well, which is the expensive part, because it takes months to notice and longer to undo.

What this paper doesn't touch is the part of fibromyalgia that answers to attention rather than to medication. Whatever is making the sensory system report ordinary pressure as pain, whether that sits in the blood or the spinal cord or both at once, the system doing the reporting is one that learns. It takes in information from movement all day and adjusts. Slow movement, done without hurry, where you only go where it feels easy, pleasant and comfortable, feeds that system input with no threat in it, repeated often enough to register as evidence. That is the mechanism the Feldenkrais Method® works through, and it's a different one from what a drug uses. Neither rules out the other. Medication and testing questions belong with your rheumatologist, and gentle awareness work sits alongside what your physiotherapist has given you rather than in place of it.

The next version of this trial will have to start by finding the people who carry the antibodies, which means someone has to build a test that can spot them. Goebel's disclosure at the bottom of the paper mentions a pending patent on exactly that, a serum assay for fibromyalgia, filed by Johns Hopkins. So the open question this study leaves is not really whether antibodies matter. It's whether they matter in your case, and for now there is no blood test anywhere that can answer it. Which leaves the same morning that was there before the paper came out. A body that has to be got upright and moved somehow, on the information you already have.